The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Cytokinetics Inc
XMUN:KK3A
|
US |
|
J
|
JCDecaux SE
F:DCS
|
FR |
|
B
|
Bakrie Telecom Tbk PT
IDX:BTEL
|
ID |
|
Repay Holdings Corp
F:0YR
|
US |
|
S
|
Scorpio Gold Corp
OTC:SRCRF
|
CA |
|
E
|
Equifax Inc
XMUN:EFX
|
US |
|
Dian Swastatika Sentosa Tbk PT
IDX:DSSA
|
ID |
|
First Hartford Corp
OTC:FHRT
|
US |
|
E
|
Esotiq & Henderson SA
WSE:EAH
|
PL |
|
T
|
ToolGen Inc
KOSDAQ:199800
|
KR |
|
Sasol Ltd
NYSE:SSL
|
ZA |
|
Sinclairs Hotels Ltd
NSE:SINCLAIR
|
IN |
|
R
|
Revvity Inc
DUS:PKN
|
US |
|
Old Second Bancorp Inc
NASDAQ:OSBC
|
US |
|
G
|
Great-West Lifeco Inc
F:GWS
|
CA |
|
Leonteq AG
SIX:LEON
|
CH |
|
S
|
Sasol Ltd
JSE:SOL
|
ZA |
|
N
|
NiCAN Ltd
OTC:NILTF
|
CA |
|
Avante Corp
XTSX:XX
|
CA |
Cytokinetics Inc (KK3A)’s 12-month stock price forecast through October 2027 has a consensus target of €98.24, implying 79% upside. The forecast is based on price targets from 22 Wall Street analysts.
Past growth per year Not enough data
Average annual growth cannot be calculated for these periods.
Explore analyst estimates, growth and forecast ranges.
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
According to Wall Street analysts, the average 1-year price target for
KK3A is 98.24 EUR with a low forecast of 73.64 EUR and a high forecast of 137.98 EUR.
Over the last 13 years, the compound annual growth rate for Revenue has been 21%. The projected CAGR for the next 8 years is 65%.
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more